BriaCell Therapeutics Corp.
BCTX
$4.35
-$0.06-1.36%
NASDAQ
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.20% | -4.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.71% | 35.18% | |||
| Operating Income | 2.71% | -35.18% | |||
| Income Before Tax | -1.40% | -31.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.40% | -31.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 11.14% | -25.82% | |||
| Net Income | -1.31% | -32.06% | |||
| EBIT | 2.71% | -35.18% | |||
| EBITDA | 2.71% | -35.32% | |||
| EPS Basic | 52.83% | 43.75% | |||
| Normalized Basic EPS | 52.67% | 43.12% | |||
| EPS Diluted | 52.89% | 43.68% | |||
| Normalized Diluted EPS | 52.67% | 43.12% | |||
| Average Basic Shares Outstanding | 114.79% | 134.77% | |||
| Average Diluted Shares Outstanding | 114.79% | 134.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||